Hitoshi Endou

Yokohama, 2300046, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies.

Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies.

Journal: Drug design, development and therapy

Published: June 26, 2024

Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.

Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.

Journal: Journal of pharmacological sciences

Published: December 19, 2023

Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation.

Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation.

Journal: Journal of pharmacological sciences

Published: December 14, 2023

Retraction: Nuclear Morphometric Analysis of Leydig Cells of Male Pubertal Rats Exposed In Utero to Di(n-butyl) Phthalate.

Retraction: Nuclear Morphometric Analysis of Leydig Cells of Male Pubertal Rats Exposed In Utero to Di(n-butyl) Phthalate.

Journal: Journal of toxicologic pathology

Published: October 23, 2023

Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.

Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.

Journal: Scientific reports

Published: April 19, 2023

Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.

Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.

Journal: Cancer cell international

Published: April 07, 2023

LAT1 enables T cell activation under inflammatory conditions.

LAT1 enables T cell activation under inflammatory conditions.

Journal: Journal of autoimmunity

Published: January 25, 2023

JPH203, a LAT1 inhibitor, alleviates steroid-resistant murine airway inflammation mediated by Th17 cells.

JPH203, a LAT1 inhibitor, alleviates steroid-resistant murine airway inflammation mediated by Th17 cells.

Journal: Allergy

Published: November 16, 2022

Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1.

Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1.

Journal: Cancer & metabolism

Published: August 02, 2022

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment.

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment.

Journal: Blood advances

Published: June 06, 2022

Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.

Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells.

Journal: Journal of cellular and molecular medicine

Published: May 20, 2022

Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment.

Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment.

Journal: Cancer immunology, immunotherapy : CII

Published: February 18, 2022

Showing 1-12 of 60

Last Updated: 09/26/2026